Trial Profile

Effect of low-dose of tolvaptan combined with standard hydration on the incidence of contrast-induced acute kidney injury in high risk patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolvaptan (Primary)
Indications Acute kidney injury; Drug toxicity
Focus Therapeutic Use

Most Recent Events

27 May 2025 New trial record
01 May 2025 Results investigating the effect of low-dose tolvaptan combined with hydration on the incidence of contrast-induced acute kidney injury (CI-AKI) and prognosis in high-risk patients undergoing coronary angiography or intervention published in the Renal Failure.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com